International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Recent advances in stem cell therapy for Parkinson’s Disease: A Review

Mohammed Ashif, Nuseba Shehla Jeelani K, Vishnupriya J, Shripriya K, Muhamed Rinoob J

Karpagam College of Pharmacy, Coimbatore, Tamil Nadu, India

Article Information

Volume / Issue2 / 4 (October-December 2021)
Pages34-39
AccessOpen Access

Publication Timeline

  • Received25 October 2021
  • Accepted13 November 2021

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Parkinson's disease (PD) is a degenerative neurological condition characterized by tremor, bradykinesia, and stiffness as cardinal motor characteristics. It's linked to a long-term loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc), resulting in a severe DA shortage in the striatum, which is necessary for motor function. There is presently no cure for Parkinson's disease, and the majority of treatments aimed at reversing dopamine depletion and alleviating symptoms. The transplantation of stem cells or stem cell derived progenitors has highlighted the potential of employing cell-based therapy to replace lost cells in the sick brain, based on promising findings from early experiments. Embryonic stem cells (ESCs) are highly expandable and pluripotent cells that can differentiate into any cell type in the human body, including nervous system tissues, suggesting that they could provide a long-term treatment for Parkinson's disease and other neurological illnesses. However, because of the potential for safety and ethical difficulties involved with the use of undifferentiated ESCs in people, other sources of transplantable cells must be considered. Another method is to use external manipulation to stimulate endogenous stem cells to heal the brain.rnRecent advances in stem cell research in Parkinson's disease will be discussed in this review, which will provide an overview of the various sources and strategies such as the use of different stem cell populations for cell replacement and possible modulation of endogenous stem cells, that have the potential to provide effective cell-based therapy in the future.

Keywords

Parkinson's diseaseStem cell therapy

References

  1. DeMaagd G, Philip A. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P & T: A peer-reviewed journal for formulary management. 2015; 40(8):504-32. PubMed PMID: 26236139; PubMed Central PMCID: PMCPMC4517533. eng. [Google Scholar][Crossref]
  2. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiology of disease. 2010; 40(1):216-21. Doi: 10.1016/j.nbd.2010.05.028. PubMed PMID: 20594979; Eng. [Google Scholar][Crossref]
  3. Lindvall O, Björklund A. Cell therapy in Parkinson's disease. Neuro Rx: the journal of the American Society for Experimental Neuro Therapeutics. 2004; 1(4):382-93. Doi: 10.1602/neurorx.1.4.382. PubMed PMID: 15717042; PubMed Central PMCID: PMCPMC534947. eng. [Google Scholar][Crossref]
  4. Han F, Baremberg D, Gao J, et al. Development of stem cell-based therapy for Parkinson's disease. Translational neurodegeneration. 2015; 4:16. Doi: 10.1186/s40035-015-0039-8. PubMed PMID: 26339485; PubMed Central PMCID: PMCPMC4559356. Eng. [Google Scholar][Crossref]
  5. Hagell P, Piccini P, Björklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nature neuroscience. 2002; 5(7):627-8. Doi: 10.1038/nn863. PubMed PMID: 12042822; eng. [Google Scholar][Crossref]
  6. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC medicine. 2012; 10:1. Doi: 10.1186/1741-7015-10-1. PubMed PMID: 22216957; PubMed Central PMCID: PMCPMC3261810. Eng. [Google Scholar][Crossref]
  7. Dunnett SB, Björklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2001; 2(5):365-9. doi: 10.1038/35072572. PubMed PMID: 11331920; Eng. [Google Scholar][Crossref]
  8. Tan HK, Toh CX, Ma D, et al. Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. Stem cells translational medicine. 2014; 3(5):586-98. Doi: 10.5966/sctm.2013-0195.PubMed PMID: 24646489; PubMed Central PMCID: PMCPMC4006490. eng. [Google Scholar][Crossref]
  9. Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circulation research. 2013; 112(3):523-33. Doi: [Google Scholar][Crossref]
  10. 1161/circresaha.111.256149. PubMed PMID: 23371901; Eng. 10. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotechnology. 2008; 26(11):1276-1284. Doi: 10.1038/nbt.1503. [Google Scholar][Crossref]
  11. Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. The Journal of clinical investigation. 2004; 113(12):1701-10. Doi: 10.1172/jci20935. PubMed PMID: 15199405; PubMed Central PMCID: PMCPMC420509. eng. [Google Scholar][Crossref]
  12. Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. The Journal of clinical investigation. 2005; 115(1):102-9. Doi: 10.1172/jci21137. PubMed PMID: 15630449; PubMed Central PMCID: PMCPMC539189. eng. [Google Scholar][Crossref]
  13. Park S, Lee KS, Lee YJ, et al. Generation of dopaminergic neurons in vitro from human embryonic stem cells treated with neurotrophic factors. Neuroscience letters. 2004; 359(1-2):99-103. Doi: 10.1016/j.neulet.2004.01.073. PubMed PMID: 15050721; Eng. [Google Scholar][Crossref]
  14. Kim JH, Auerbach JM, Rodríguez-Gómez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002; 418(6893):50-6. Doi: 10.1038/nature00900. PubMed PMID: 12077607; eng. [Google Scholar][Crossref]
  15. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science (New York, NY). 1998; 282(5391):1145-7. Doi: 10.1126/science.282.5391.1145.International Journal of Medical and all body Health Research www.allmedicaljournal.com 38 PubMed PMID: 9804556; Eng. [Google Scholar][Crossref]
  16. Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011; 480(7378):547-51. Doi: 10.1038/nature10648. PubMed PMID: 22056989; PubMed Central PMCID: PMCPMC3245796. Eng. [Google Scholar][Crossref]
  17. Roy NS, Cleren C, Singh SK, et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nature medicine. 2006; 12(11):1259-68. Doi: 10.1038/nm1495. PubMed PMID: 17057709; eng. [Google Scholar][Crossref]
  18. Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem cells (Dayton, Ohio). 2006; 24(6):1433-40. Doi: 10.1634/stemcells.2005-0393. PubMed PMID: 16556709; Eng. [Google Scholar][Crossref]
  19. Grealish S, Diguet E, Kirkeby A, et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell stem cell. 2014; 15(5):653-65. doi: 10.1016/j.stem.2014.09.017. PubMed PMID: 25517469; PubMed Central PMCID: PMCPMC4232736. Eng. [Google Scholar][Crossref]
  20. Sánchez-Danés A, Consiglio A, Richaud Y, et al. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther. 2012; 23(1):56-69. Doi: 10.1089/hum.2011.054. PubMed PMID: 21877920; PubMed Central PMCID: PMCPMC3472681. Eng. [Google Scholar][Crossref]
  21. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009; 136(5):964-77. Doi: 10.1016/j.cell.2009.02.013.PubMed PMID: 19269371; PubMed Central PMCID: PMCPMC2787236. eng. [Google Scholar][Crossref]
  22. Kikuchi T, Morizane A, Doi D, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature. 2017; 548(7669):592-596. Doi: 10.1038/nature23664. PubMed PMID: 28858313; Eng. [Google Scholar][Crossref]
  23. Shim JW, Park CH, Bae YC, et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem cells (Dayton, Ohio). 2007; 25(5):1252-62. Doi: 10.1634/stemcells.2006-0274. PubMed PMID: 17234994; Eng. [Google Scholar][Crossref]
  24. Offen D, Barhum Y, Levy YS, et al. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. Journal of neural transmission Supplementum. 2007 (72):133-43. Doi: 10.1007/978-3-211-73574-9_16. PubMed PMID: 17982886; Eng. [Google Scholar][Crossref]
  25. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Molecular biology of the cell. 2002; 13(12):4279-95. Doi: 10.1091/mbc.e02-02-0105. PubMed PMID: 12475952; PubMed Central PMCID: PMCPMC138633. eng. [Google Scholar][Crossref]
  26. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. British journal of haematology. 2000; 109(1):235-42. Doi: 10.1046/j.1365-2141.2000.01986.x. PubMed PMID: 10848804; Eng. [Google Scholar][Crossref]
  27. Gronthos S, Mankani M, Brahim J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(25):13625-30. doi: 10.1073/pnas.240309797. PubMed PMID: 11087820; PubMed Central PMCID: PMCPMC17626. Eng. [Google Scholar][Crossref]
  28. Paul G, Özen I, Christophersen NS, et al. The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One. 2012; 7(4):e35577. Doi: 10.1371/journal.pone.0035577. PubMed PMID: 22523602; PubMed Central PMCID: PMCPMC3327668 AB: K.D., K.J. and A.H. Neuro Nova AB is a small Swedish biopharmaceutical company pursuing clinical trials in Parkinson's disease and Amyotrophic Lateral Sclerosis (www.neuronova.com). The company has a general interest in understanding the regenerative capacity of the adult brain but is not pursuing strategies related to commercialization of cultured stem cells or therapies based on stem cell/progenitor transplantation. The company has not sponsored the work performed at the academic institutions. The company employees being co-authors on the manuscript have not been influenced by commercial interest interpreting the data. The authors being employees at Neuro Nova AB does also not alter the authors' adherence to all PLoS ONE policies on sharing data and materials. eng. [Google Scholar][Crossref]
  29. Kim TW, Koo SY, Studer L. Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities. Front Cell Dev Biol. 2020; 8:729. Doi: 10.3389/fcell.2020.00729. PubMed PMID: 32903681; PubMed Central PMCID: PMCPMC7438741. [Google Scholar][Crossref]
  30. Phanstiel DH, Brumbaugh J, Wenger CD, et al. Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nature methods. 2011; 8(10):821-7. Doi: 10.1038/nmeth.1699. PubMed PMID: 21983960; PubMed Central PMCID: PMCPMC3432645. eng. [Google Scholar][Crossref]
  31. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011; 471(7336):68-73. Doi: 10.1038/nature09798. PubMed PMID: 21289626; PubMed Central PMCID: PMCPMC3100360. eng. [Google Scholar][Crossref]
  32. Cyranoski D. Stem-cell pioneer banks on future therapies. Nature. 2012; 488(7410):139. Doi: 10.1038/488139a. PubMed PMID: 22874941; eng. [Google Scholar][Crossref]
  33. Caiazzo M, Dell’Anno MT, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature. 2011; 476(7359):224-227. Doi: 10.1038/nature10284. [Google Scholar][Crossref]
  34. Liu X, Li F, Stubblefield EA, et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Research. 2012; 22(2):321-332. Doi: 10.1038/cr.2011.181. [Google Scholar][Crossref]
  35. Kim HS, Kim J, Jo Y, et al. Direct lineage reprogramming of mouse fibroblasts to functional midbrain dopaminergic neuronal progenitors. Stem Cell Research. 2014; 12(1):60-68. Doi: https://doi.org/10.1016/j.scr.2013.09.007.International Journal of Medical and all body Health Research www.allmedicaljournal.com 39 [Google Scholar][Crossref]
  36. Kim J, Su Susan C, Wang H, et al. Functional Integration of Dopaminergic Neurons Directly Converted from Mouse Fibroblasts. Cell stem cell. 2011; 9(5):413-419. Doi: 10.1016/j.stem.2011.09.011. [Google Scholar][Crossref]
  37. Kalia LV, Lang AE. Parkinson's disease. The Lancet. 2015; 386(9996):896-912. Doi: 10.1016/S0140-6736(14)61393-3. [Google Scholar][Crossref]
  38. Hayashi T, Wakao S, Kitada M, et al. Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. The Journal of clinical investigation. 2013; 123(1):272-84. Doi: 10.1172/jci62516. PubMed PMID: 23202734; PubMed Central PMCID: PMCPMC3533267. Eng. [Google Scholar][Crossref]
  39. Jang SE, Qiu L, Chan LL, et al. Current Status of Stem Cell-Derived Therapies for Parkinson’s Disease: From Cell Assessment and Imaging Modalities to Clinical Trials [Review]. Frontiers in Neuroscience. 2020, 14(1077). doi: 10.3389/fnins.2020.558532. English. [Google Scholar][Crossref]

How to Cite

Ashif, M., K, N. S. J., J, V., K, S., & J, M. R. (2021). Recent advances in stem cell therapy for Parkinson’s Disease: A Review. International Journal of Medical and All Body Health Research, 2(4), 34-39. https://doi.org/10.54660/Ijmabhr.2021.2.4.1

Ashif, Mohammed, et al. "Recent advances in stem cell therapy for Parkinson’s Disease: A Review." International Journal of Medical and All Body Health Research, vol. 2, no. 4, 2021, pp. 34-39. https://doi.org/10.54660/Ijmabhr.2021.2.4.1.

Ashif, M., K, N. S. J., J, V., K, S. and J, M. R. (2021) 'Recent advances in stem cell therapy for Parkinson’s Disease: A Review', International Journal of Medical and All Body Health Research, 2(4), pp. 34-39. doi: 10.54660/Ijmabhr.2021.2.4.1.

Ashif M, K NSJ, J V, K S, J MR. Recent advances in stem cell therapy for Parkinson’s Disease: A Review. International Journal of Medical and All Body Health Research. 2021;2(4):34-39. doi:10.54660/Ijmabhr.2021.2.4.1

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.